



BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

## Low-value clinical practices in adult traumatic brain injury: an umbrella review protocol

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-031747
Article Type:	Protocol
Date Submitted by the Author:	16-May-2019
Complete List of Authors:	<p>Tardif, Pier-Alexandre; Population Health and Optimal Health Practices Research Unit, Trauma – Emergency – Critical Care Medicine, Centre de Recherche du CHU de Québec – Université Laval (Hôpital de l'Enfant-Jésus), Université Laval</p> <p>Moore, Lynne; Population Health and Optimal Health Practices Research Unit, Trauma – Emergency – Critical Care Medicine, Centre de Recherche du CHU de Québec – Université Laval (Hôpital de l'Enfant-Jésus), Université Laval; Department of Social and Preventative Medicine, Université Laval</p> <p>Lauzier, François; Population Health and Optimal Health Practices Research Unit, Trauma – Emergency – Critical Care Medicine, Centre de Recherche du CHU de Québec – Université Laval (Hôpital de l'Enfant-Jésus), Université Laval; Department of Social and Preventative Medicine, Université Laval</p> <p>Farhat, Imen; Population Health and Optimal Health Practices Research Unit, Trauma – Emergency – Critical Care Medicine, Centre de Recherche du CHU de Québec – Université Laval (Hôpital de l'Enfant-Jésus), Université Laval; Department of Social and Preventative Medicine, Université Laval</p> <p>Archambault, Patrick; Population Health and Optimal Health Practices Research Unit, Trauma – Emergency – Critical Care Medicine, Centre de Recherche du CHU de Québec – Université Laval (Hôpital de l'Enfant-Jésus), Université Laval; Department of Anesthesiology and Critical Care Medicine, Division of Critical Care Medicine, Université Laval</p> <p>Lamontagne, Francois; Department of Medicine, Université de Sherbrooke, 3001, 12th Avenue North</p> <p>Chassé, Michael; Department of Medicine, Université de Montréal</p> <p>Stelfox, Henry; Departments of Critical Care Medicine, Medicine and Community Health Sciences, O'Brien Institute for Public Health, University of Calgary</p> <p>Gabbe, Belinda; Monash University School of Public Health and Preventive Medicine; Farr Institute, Swansea University Medical School, Swansea University</p> <p>Lecky, Fiona; The University of Sheffield School of Health and Related Research</p> <p>Kortbeek, John; Department of Surgery, University of Calgary</p> <p>Lessard-Bonaventure, Paule; Population Health and Optimal Health Practices Research Unit, Trauma – Emergency – Critical Care Medicine, Centre de Recherche du CHU de Québec – Université Laval (Hôpital de l'Enfant-Jésus), Université Laval; Department of Surgery, Division of Neurosurgery, Université Laval</p>

	Truchon, Catherine; Institut national d'excellence en santé et en services sociaux du Québec
	Turgeon, Alexis; Department of Social and Preventative Medicine, Université Laval; Department of Anesthesiology and Critical Care Medicine, Division of Critical Care Medicine, Université Laval
Keywords:	Low-value clinical practices, traumatic brain injury, umbrella review



# LOW-VALUE CLINICAL PRACTICES IN ADULT TRAUMATIC BRAIN INJURY: AN UMBRELLA REVIEW PROTOCOL

Pier-Alexandre Tardif, MA MSc<sup>1</sup> ([pier-alexandre.tardif@crchudequebec.ulaval.ca](mailto:pier-alexandre.tardif@crchudequebec.ulaval.ca))

Lynne Moore, PhD<sup>1, 2</sup> ([lynne.moore@fmed.ulaval.ca](mailto:lynne.moore@fmed.ulaval.ca))

François Lauzier MD MSc<sup>1,3</sup> ([Francois.Lauzier@fmed.ulaval.ca](mailto:Francois.Lauzier@fmed.ulaval.ca))

Imen Farhat MSc<sup>1,2</sup> ([Imen.Farhat.1@ulaval.ca](mailto:Imen.Farhat.1@ulaval.ca))

Patrick Archambault<sup>1,3,4,5</sup> ([patrick.m.archambault@gmail.com](mailto:patrick.m.archambault@gmail.com))

François Lamontagne MD MSc<sup>6</sup> ([Francois.Lamontagne@usherbrooke.ca](mailto:Francois.Lamontagne@usherbrooke.ca))

Michael Chassé MD PhD<sup>7</sup> ([Michael.Chasse@umontreal.ca](mailto:Michael.Chasse@umontreal.ca))

Henry T Stelfox MD PhD<sup>8</sup> ([tstelfox@ucalgary.ca](mailto:tstelfox@ucalgary.ca))

Belinda Gabbe PhD<sup>9,10</sup> ([Belinda.Gabbe@monash.edu](mailto:Belinda.Gabbe@monash.edu))

Fiona Lecky MD MSc<sup>11</sup> ([f.e.lecky@sheffield.ac.uk](mailto:f.e.lecky@sheffield.ac.uk))

John Kortbeek MD<sup>12</sup> ([John.Kortbeek@albertahealthservices.ca](mailto:John.Kortbeek@albertahealthservices.ca))

Paule Lessard Bonaventure MD MSc<sup>1,13</sup> ([Paule.Lessard-Bonaventure.1@ulaval.ca](mailto:Paule.Lessard-Bonaventure.1@ulaval.ca))

Catherine Truchon PhD<sup>14</sup> ([Catherine.Truchon@inesss.qc.ca](mailto:Catherine.Truchon@inesss.qc.ca))

Alexis F Turgeon MD MSc<sup>1,2,3</sup> ([Alexis.Turgeon@fmed.ulaval.ca](mailto:Alexis.Turgeon@fmed.ulaval.ca))

on behalf of the Canadian Traumatic Brain Injury Research Consortium

<sup>1</sup>Population Health and Optimal Health Practices Research Unit, Trauma – Emergency – Critical Care Medicine, Centre de Recherche du CHU de Québec – Université Laval (Hôpital de l'Enfant-Jésus), Université Laval, Québec (QC), Canada

<sup>2</sup>Department of Social and Preventative Medicine, Université Laval, Québec (QC), Canada

<sup>3</sup>Department of Anesthesiology and Critical Care Medicine, Division of Critical Care Medicine, Université Laval, Québec City, Québec, Canada

<sup>4</sup>Centre intégré de santé et de services sociaux de Chaudière-Appalaches, Ste-Marie (QC), Canada

<sup>5</sup>Département de médecine familiale et médecine d'urgence, Université Laval, Québec (QC), Canada

<sup>6</sup>Department of Medicine, Université de Sherbrooke, 3001, 12th Avenue North, Sherbrooke, Québec, Canada

<sup>7</sup>Department of Medicine, Université de Montréal, Montréal, Québec, Canada

1  
2  
3 32 <sup>8</sup>Departments of Critical Care Medicine, Medicine and Community Health Sciences, O'Brien  
4 33 Institute for Public Health, University of Calgary, Calgary, Alberta, Canada  
5  
6 34 <sup>9</sup>School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia  
7  
8 35 <sup>10</sup>Farr Institute, Swansea University Medical School, Swansea University, Swansea, UK  
9  
10 36 <sup>11</sup>School of Health and Related Research, University of Sheffield, Sheffield, United Kingdom;  
11 Trauma Audit and Research Network, United Kingdom  
12  
13 38 <sup>12</sup>Department of Surgery, University of Calgary, Calgary, Alberta, Canada  
14  
15 39 <sup>13</sup>Department of Surgery, Division of Neurosurgery, Université Laval, Québec (QC), Canada  
16  
17 40 <sup>14</sup>Institut national d'excellence en santé et en services sociaux, Québec (QC), Canada  
18  
19 41

20 42 **Corresponding author and address for reprints:**  
21  
22 43 Pier-Alexandre Tardif  
23  
24 44 CHU de Québec-Université Laval Research Center (Enfant-Jésus Hospital)  
25  
26 45 Axe Santé des Populations et Pratiques Optimales en Santé (Population Health and Optimal Health  
27  
28 46 Practices Research Unit), Traumatologie – Urgence - Soins intensifs (Trauma – Emergency –  
29  
30 47 Critical Care Medicine)  
31  
32 48 1401, 18e rue, local H-012a, Québec (Québec), G1J 1Z4  
33  
34 49 Tel. 418-649-0252 #66605  
35  
36 50 Fax: 418-649-5733  
37  
38 51 Email: pier-alexandre.tardif@crchudequebec.ulaval.ca  
39  
40 52

41  
42 53 **Keywords:** Low-value clinical practices, traumatic brain injury, umbrella review

43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54 54 **Running head:** Umbrella review on low-value practices in acute TBI care  
55  
56  
57  
58  
59  
60

## ABSTRACT

**Introduction:** Traumatic brain injury (TBI) leads to 50,000 deaths, 85,000 disabilities and costs \$60 billion each year in the USA. Despite numerous interventions and treatment options, the outcomes of TBI have improved little over the last three decades. In a previous scoping review and expert consultation survey, we identified 15 potentially low-value clinical practices in acute TBI. The objective of this umbrella review is to synthesize the evidence on potentially low-value clinical practices in the care of acute TBI.

**Methods and analysis:** Using umbrella review methodology, we will search Cochrane CENTRAL, EMBASE, Epistemonikos, PROSPERO and PubMed to identify systematic reviews evaluating the effect of potential intra-hospital low-value practices. We will present data on the methodological quality of these reviews (AMSTAR-2), reported effect sizes and the strength of evidence (GRADE).

**Ethics and dissemination:** Ethics approval is not required as original data will not be collected. Knowledge users from five healthcare quality organisations and clinical associations are involved in the design and conduct of the study. Results will be disseminated in a peer-reviewed journal, at international scientific meetings and to clinical, healthcare quality and patient-partner associations. This work will support the development of metrics to measure the use of low-value practices, inform policy makers on potential targets for de-implementation, and in the long term reduce the use of low-value clinical practices in acute TBI care.

**Registration details:** The protocol is currently under evaluation with the International Prospective Register of Systematic Reviews (PROSPERO).

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

STRENGTHS AND LIMITATIONS OF THIS STUDY

- State-of-the-art synthesis of evidence on low-value clinical practices in the care of acute TBI
- Represents a crucial step towards the de-implementation of low-value practices in acute TBI care
- Adopts an integrated knowledge translation model to ensure the results are relevant to decision makers
- For feasibility reasons, our synthesis is restricted to systematic reviews published in English since 1990
- The scope of review and the inclusion of systematic reviews precludes meta-analysis

## INTRODUCTION

Traumatic brain injury (TBI) is the main cause of mortality from injury in people under 45 years of age[1] and it leads to approximately US\$60 and €33 billion in total medical costs in the USA[2] and Europe[3] each year, respectively. Moreover, outcomes following TBI have not improved significantly in the last four decades.[4, 5] Intervention and treatment options for TBI are multiple, but many lack robust evidence of their effectiveness.[6, 7]

Low-value clinical practices, defined as a test or procedure that is not supported by evidence and/or could expose patients to unnecessary harm [8-15] consume up to 30% of healthcare budgets.[9, 16] In the past decade, the medical community has turned towards the de-implementation of low-value practices as a promising means to reduce the strain on healthcare budgets, free-up resources and reduce harm to patients.[17] Physicians report using low-value practices because of a lack of alternative treatment options, fear of legal consequences but also because of lack of guidelines on low-value care.[15, 18] The *Brain Trauma Foundation*, among others, publish guidelines on TBI care.[19] However, emphasis is on practices that should be adhered to rather than practices that should be avoided. *Choosing Wisely* publish recommendations specifically targeting low-value practices but few pertain to TBI care and many are based uniquely on expert consensus.[11] A previous scoping review and expert consultation survey identified 13 potentially low-value clinical practices in acute TBI care.[20] These practices represent potential targets for guidelines, overuse metrics and de-implementation interventions. However, before recommendations can be made, we need to synthesize the evidence base for these practices.

Interventions and treatment options for acute TBI have been the subject of multiple systematic reviews.[21, 22] Given this large body of available evidence, evidence maps have previously been used to summarize evidence from systematic reviews on acute TBI interventions.[7, 23] However, these evidence maps were not designed to target low-value practices and focused on moderate to severe TBI when the mild TBI population represent great potential for reducing low-value care. In addition, previous reviews have not provided a synthesis of effect sizes or strength of evidence. The objective of the present study is to synthesize the evidence on potentially low-value intra-hospital clinical practices in acute adult TBI.



1  
2  
3 117 METHODS AND ANALYSIS  
4  
5 118 Given the multitude of systematic reviews available for the clinical practices identified as  
6  
7 119 potentially low-value (over 60 were identified in our scoping review), we opted to conduct an  
8  
9 120 umbrella review.[20] The review will be conducted according to published guidelines.[24-26] In  
10  
11 121 the absence of reporting guidelines for umbrella reviews, we will use the applicable Preferred  
12  
13 122 Reporting Items for Systematic Reviews and Meta-Analysis Protocols (PRISMA-P).[27] The  
14  
15 123 protocol is currently under evaluation with the International Prospective Register of Systematic  
16  
17 124 Reviews (PROSPERO).  
18

19 126 **Eligibility criteria**

20 127 The project steering committee comprising clinicians (2 emergency physicians, 7 critical care  
21  
22 128 physicians, 1 neurosurgeon), methodologists (4), and health system managers (3) used the  
23  
24 129 population, intervention, comparator, outcome and study design (PICOS) framework to develop  
25  
26 130 specific research questions for each potentially low-value clinical practice (Table 1).[20, 28] We  
27  
28 131 will consider systematic reviews of original studies evaluating the effectiveness of pre-determined  
29  
30 132 clinical practices in acute TBI in adults ( $\geq 16$  years old), without restriction on location of  
31  
32 133 publication but limited to studies published in English since 1990.[25, 26]  
33

34 135 We will use the Cochrane definition to identify systematic reviews. We will consider a review to  
35  
36 136 be systematic if it clearly stated a set of objectives and reported explicit eligibility criteria, an  
37  
38 137 extensive search strategy (a refined search strategy ran on MEDLINE or Cochrane Library and at  
39  
40 138 least one other database)[29, 30] and reproducible methods to identify, select, and critically  
41  
42 139 appraise the findings of the included studies.[24]  
43

44 141 **Outcomes**

45  
46 142 Primary and secondary outcomes were identified for each of the evaluated clinical practices by the  
47  
48 143 project steering committee and are described in a PICO format in Table 1.  
49

50 144  
51 145 **Search strategy**

52  
53 146 In consultation with an information specialist, we will develop comprehensive literature search  
54  
55 147 strategies separately for each clinical practice to be studied (see Table 2 for a preliminary search  
56  
57  
58  
59  
60

strategy in PubMed). We will search systematic reviews using the Cochrane Library, Excerpta Medica Database (EMBASE), Epistemonikos,[31] PubMed and the International Prospective Register of Systematic Reviews (PROSPERO)[32] from 1990 to up to six months prior to submission for publication. Using a snowball approach, we will screen the references of included studies in addition to previous reviews on this subject.[7, 21-23, 33]

### **Selection process**

We will manage all citations with EndNote software (version X8.2, Clarivate Analytics, 2014). We will identify and remove duplicates using electronic and manual screening.[34] To ensure reliability when selecting studies for a given practice, two sets of 100 citations will independently be evaluated and then discussed by the reviewers. Pairs of reviewers (PAT, LM, IF, KMB) will then independently screen all identified records using titles, abstracts and full texts, consecutively. Any disagreement will be resolved through discussion between reviewers and, if necessary, consultation with a senior author (AFT). Potentially eligible studies excluded using full texts will be described in a PRISMA flow chart.

### **Data items and abstraction process**

Using a standardized data abstraction form piloted on a representative sample of 5 studies, pairs of experienced reviewers (PAT, LM, IF, KMB) will independently extract the following data: first author, title, year of publication, databases used and date of the last search; population(s), intervention(s), comparator(s), outcome(s) and study designs included; measures of association and their respective measure of heterogeneity; tools used to assess the quality (risk of bias) of original studies and overall rating from the authors. Any disagreement will be resolved through discussion between reviewers and, if necessary, consultation with a senior author (AFT). When information is available in figures only, we will abstract graphical data using computer-assisted software.[35, 36] Furthermore, we will contact study authors (up to three email attempts) when information is unclear or unavailable.

### **Methodological quality assessment**

Two reviewers (PAT, LM) will independently critically appraise the quality of systematic reviews using the Assessing the Methodological Quality of Systematic Reviews (AMSTAR-2) tool.[37] Methodological quality will be categorised as low (0-3), medium (4-7) and high (8-11).

**Level of evidence**

Strength of recommendations will be assessed independently by pairs of content experts using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) tool for diagnostic[38] or therapeutic[39] procedures.

**Synthesis**

Results will be presented according to current recommendations for umbrella reviews.[40] For each low-value practice, we will present the number of reviews (and patients) included, the quality of the reviews (AMSTAR-2), effect sizes for primary and secondary outcomes (forest plots) and strength of recommendations (GRADE).

**Potential limitations**

To ensure the feasibility of the review, we will restrict our search to low-value practices identified in the scoping review and expert consultation study, which may lead us to miss some low-value practices. However, given the robust search strategy used in our scoping review and the fact that experts were asked to add any other practices they considered low-value, it is unlikely that important low-value practices have been missed. By targeting systematic reviews rather than original studies, we may miss some evidence. However, given the availability of high-quality, up-to-date reviews in TBI care suggested by our scoping review, we think it unlikely that we will miss a large body of evidence. For certain clinical practices, we may not identify any high-quality, up-to-date reviews. These practices will be the subject of systematic reviews in subsequent phases of the research program. Finally, for feasibility reasons, we limited this umbrella review to reviews published in English since 1990 as per recommendations for umbrella reviews.[25, 26] These limitations should have negligible impact on results since few systematic reviews were published prior to 1990 and most published reviews are likely to be written in English.[25, 26]

**Potential impact**

This review is part of the *Canadian Program on Monitoring Low-Value Clinical Practices in Injury Care* (Canadian Institutes of Health Research #113664), aiming to evaluate the effectiveness of an audit-feedback module targeting low-value clinical practices in acute injury care. The results of this review will be used to inform the development of quality indicators to be integrated in the audit-feedback module.

We will use state-of-the-art methods to optimize the sensitivity of our search strategy and the robustness of results. Results will be synthesized graphically. Ultimately, this research will inform the development of metrics, guidelines and de-implementation interventions, all targeting low-value injury care. The reduction of low-value clinical practices in acute TBI care has the potential to reduce pressure on strained healthcare budgets, free up resources, reduce adverse events and improve patient outcomes.

## ETHICS AND DISSEMINATION

Ethics approval is not required as original data will not be collected. This study will be disseminated in a peer-reviewed journal, international scientific meetings, to knowledge users through clinical and healthcare quality associations (Choosing Wisely Canada, Trauma Association of Canada, American College of Surgeons – Committee on Trauma, International Federation of Emergency Medicine, Institut national d'excellence en santé et en services sociaux, Brain Trauma Foundation) and to patient partners associations (Brain Injury Canada).

## Patient and Public Involvement

No patient or public representatives will be involved in this study.

231 REFERENCES

232 1. The American Association for the Surgery of Trauma (AAST). Traumatic Brain Injury in the  
233 United States: A Report to Congress, CDC, December 1999 [cited 2018 November 19].  
234 Available from: <http://www.aast.org/trauma-facts>.  
235 2. Coronado VG, Haileyesus T, Cheng TA, et al. Trends in Sports- and Recreation-Related  
236 Traumatic Brain Injuries Treated in US Emergency Departments: The National Electronic Injury  
237 Surveillance System-All Injury Program (NEISS-AIP) 2001-2012. *J Head Trauma Rehabil*  
238 2015;30(3):185-97.  
239 3. Olesen J, Gustavsson A, Svensson M, et al. The economic cost of brain disorders in Europe.  
240 *Eur J Neurol* 2012;19(1):155-62.  
241 4. Rosenfeld JV, Maas AI, Bragge P, et al. Early management of severe traumatic brain injury.  
242 *Lancet* 2012;380(9847):1088-98.  
243 5. Maas AIR, Menon DK, Adelson PD, et al. Traumatic brain injury: integrated approaches to  
244 improve prevention, clinical care, and research. *Lancet Neurol* 2017;16(12):987-1048.  
245 6. Maas AI, Roozenbeek B, Manley GT. Clinical trials in traumatic brain injury: past experience  
246 and current developments. *Neurotherapeutics* 2010;7(1):115-26.  
247 7. Bragge P, Synnot A, Maas AI, et al. A State-of-the-Science Overview of Randomized  
248 Controlled Trials Evaluating Acute Management of Moderate-to-Severe Traumatic Brain Injury.  
249 *J Neurotrauma* 2016;33(16):1461-78.  
250 8. Boat TF, Chao SM, O'Neill PH. From waste to value in health care. *JAMA* 2008;299(5):568-  
251 71.  
252 9. Reilly BM, Evans AT. Much ado about (doing) nothing. *Annals of internal medicine*  
253 2009;150(4):270-1.  
254 10. Berwick DM, Hackbarth AD. Eliminating waste in US health care. *JAMA*  
255 2012;307(14):1513-6.  
256 11. Choosing Wisely Canada. 2015 [cited 2018 November 19]. Available from:  
257 <https://choosingwiselycanada.org/>.  
258 12. Morgan DJ, Dhruva SS, Wright SM, et al. 2016 Update on Medical Overuse: A Systematic  
259 Review. *JAMA Intern Med* 2016;176(11):1687-92.  
260 13. Berwick DM. Avoiding overuse-the next quality frontier. *Lancet* 2017;390(10090):102-4.  
261 14. Brownlee S, Chalkidou K, Doust J, et al. Evidence for overuse of medical services around the  
262 world. *Lancet* 2017;390(10090):156-68.  
263 15. Saini V, Brownlee S, Elshaug AG, et al. Addressing overuse and underuse around the world.  
264 *Lancet* 2017;390(10090):105-7.  
265 16. Fisher ES, Wennberg DE, Stukel TA, et al. The implications of regional variations in  
266 Medicare spending. Part 2: health outcomes and satisfaction with care. *Annals of internal*  
267 *medicine* 2003;138(4):288-98.  
268 17. Niven DJ, Mrklas KJ, Holodinsky JK, et al. Towards understanding the de-adoption of low-  
269 value clinical practices: a scoping review. *BMC Med* 2015;13:255.  
270 18. Emanuel EJ, Fuchs VR. The perfect storm of overutilization. *JAMA* 2008;299(23):2789-91.  
271 19. Carney N, Totten AM, O'Reilly C, et al. Guidelines for the Management of Severe Traumatic  
272 Brain Injury, Fourth Edition. *Neurosurgery* 2017;80(1):6-15.  
273 20. Moore L, Lauzier F, Tardif PA, et al. Low-Value Clinical Practices in Injury Care: A Scoping  
274 Review and Expert Consultation Survey. *J Trauma Acute Care Surg* 2019.

21. Lei J, Gao GY, Jiang JY. Is management of acute traumatic brain injury effective? A literature review of published Cochrane Systematic Reviews. *Chin J Traumatol* 2012;15(1):17-22.
22. Lu J, Gary KW, Copolillo A, et al. Randomized controlled trials in adult traumatic brain injury: a review of compliance to CONSORT statement. *Arch Phys Med Rehabil* 2015;96(4):702-14.
23. Synnot A, Bragge P, Lunny C, et al. The currency, completeness and quality of systematic reviews of acute management of moderate to severe traumatic brain injury: A comprehensive evidence map. *PLoS One* 2018;13(6):e0198676.
24. Higgins J, Green S, (editors). *Cochrane Handbook for Systematic Reviews of Interventions* Version 5.1.0 [updated March 2011]. Higgins J, Green S, editors: The Cochrane Collaboration; 2011.
25. Smith V, Devane D, Begley CM, et al. Methodology in conducting a systematic review of systematic reviews of healthcare interventions. *BMC Med Res Methodol* 2011;11(1):15.
26. The Joanna Briggs Institute. Joanna Briggs Institute Reviewers' Manual: 2014 edition / Supplement. *The Joanna Briggs Institute* 2014.
27. Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. *Syst Rev* 2015;4:1.
28. Stone PW. Popping the (PICO) question in research and evidence-based practice. *Appl Nurs Res* 2002;15(3):197-8.
29. Marshall I, Marshall R, Wallace B, et al. Rapid reviews may produce different results to systematic reviews: a meta-epidemiological study. *J Clin Epidemiol* 2018.
30. Bramer WM, Rethlefsen ML, Kleijnen J, et al. Optimal database combinations for literature searches in systematic reviews: a prospective exploratory study. *Systematic reviews* 2017;6(1):245-.
31. Epistemonikos. Epistemonikos n.d. [cited 2018 November 19]. Available from: <http://www.epistemonikos.org/en/>.
32. Centre for Reviews and Dissemination. PROSPERO [cited 2018 November 19]. Available from: <https://www.crd.york.ac.uk/PROSPERO/>.
33. Horton L, Rhodes J, Wilson L. Randomized Controlled Trials in Adult Traumatic Brain Injury: A Systematic Review on the Use and Reporting of Clinical Outcome Assessments. *J Neurotrauma* 2018;35(17):2005-14.
34. Bramer WM, Giustini D, de Jonge GB, et al. De-duplication of database search results for systematic reviews in EndNote. *J Med Libr Assoc* 2016;104(3):240-3.
35. de Oliveira IR, Santos-Jesus R, Po AL, et al. Extracting numerical data from published reports of pharmacokinetics investigations: method description and validation. *Fundam Clin Pharmacol* 2003;17(4):471-2.
36. Robson RC, Pham B, Hwee J, et al. Few studies exist examining methods for selecting studies, abstracting data, and appraising quality in a systematic review. *J Clin Epidemiol* 2018.
37. Shea BJ, Reeves BC, Wells G, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. *BMJ* 2017;358:j4008.
38. Schunemann HJ, Oxman AD, Brozek J, et al. Grading quality of evidence and strength of recommendations for diagnostic tests and strategies. *BMJ* 2008;336(7653):1106-10.
39. Atkins D, Best D, Briss PA, et al. Grading quality of evidence and strength of recommendations. *BMJ* 2004;328(7454):1490.



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

40. Lunny C, Brennan SE, McDonald S, et al. Toward a comprehensive evidence map of  
overview of systematic review methods: paper 2-risk of bias assessment; synthesis, presentation  
and summary of the findings; and assessment of the certainty of the evidence. *Syst Rev*  
2018;7(1):159.

For peer review only

326 **Tables**327 **Table 1. PICOS for each clinical practice**  
328

#	Clinical practice
	Mild traumatic brain injury
1	<i>Population:</i> adults with acute mild traumatic brain injury <i>Intervention:</i> validated clinical decision rule (e.g. CCHR, CHIP, NEXUS II, NOC) <i>Comparator:</i> none <i>Primary Outcome:</i> false negative rate (intracranial injury, neurosurgical intervention) <i>Secondary Outcomes:</i> sensitivity, specificity <i>Study design:</i> systematic review
2	<i>Population:</i> adults with acute mild complicated traumatic brain injury <i>Intervention:</i> routine repeat head CT in absence of neurological deterioration <i>Comparator:</i> none or no repeat head CT in absence of neurological deterioration <i>Primary Outcome:</i> progression of intracranial injury <i>Secondary Outcomes:</i> neurosurgical intervention, mortality, change in management, hospital length of stay <i>Study design:</i> systematic review
3	<i>Population:</i> adults with acute mild traumatic brain injury and on anticoagulant and/or antiplatelet therapy <i>Intervention:</i> : routine repeat head CT in absence of neurological deterioration <i>Comparator:</i> none or no repeat head CT in absence of neurological deterioration <i>Primary Outcome:</i> progression of intracranial injury <i>Secondary Outcomes:</i> neurosurgical intervention, mortality, change in management, hospital length of stay <i>Study design:</i> systematic review
4	<i>Population:</i> adults with acute mild traumatic brain injury who are negative on head CT <i>Intervention:</i> neurosurgical consultation <i>Comparator:</i> none or no neurosurgical consultation <i>Primary Outcome:</i> hospital admission <i>Secondary Outcomes:</i> neurosurgical intervention, mortality, ICU admission, repeat head CT, hospital length of stay <i>Study design:</i> systematic review
5	<i>Population:</i> adults with acute mild complicated traumatic brain injury who are not on irreversible anticoagulation <i>Intervention:</i> intensive care unit admission



	<i>Comparator:</i> admission to regular ward or step-down unit <i>Primary Outcome:</i> neurological/medical decline, neurosurgical intervention <i>Secondary Outcomes:</i> medical interventions, mortality, adverse events, hospital length of stay, discharge destination <i>Study design:</i> systematic review
Moderate and severe traumatic brain injury	
6	<i>Population:</i> adults with acute traumatic brain injury on antiplatelet therapy <i>Intervention:</i> platelet transfusion <i>Comparator:</i> no platelet transfusion <i>Primary Outcome:</i> GOS or GOS-E <i>Secondary Outcomes:</i> mortality, adverse events, hospital and ICU length of stay <i>Study design:</i> systematic review
7	<i>Population:</i> adults with basal skull fractures without evidence of cerebrospinal fluid leakage <i>Intervention:</i> antibiotic prophylaxis <i>Comparator:</i> no antibiotic prophylaxis <i>Primary Outcome:</i> meningitis (confirmed by lumbar puncture) <i>Secondary Outcomes:</i> GOS or GOS-E, mortality, surgical correction in patients with CSF leakage, non-CNS infection, hospital and ICU length of stay <i>Study design:</i> systematic review
8	<i>Population:</i> adults with acute traumatic brain injury and no refractory intracranial hypertension <i>Intervention:</i> therapeutic hypothermia <i>Comparator:</i> no therapeutic hypothermia <i>Primary Outcome:</i> GOS or GOS-E <i>Secondary Outcomes:</i> intracranial pressure, mortality, adverse events, hospital and ICU length of stay <i>Study design:</i> systematic review
9	<i>Population:</i> adults with acute traumatic brain injury <i>Intervention:</i> antibiotic prophylaxis for external ventricular drain placement <i>Comparator:</i> no antibiotic prophylaxis <i>Primary Outcome:</i> ventriculostomy-related infection <i>Secondary Outcomes:</i> GOS, mortality, hospital and ICU length of stay <i>Study design:</i> systematic review
10	<i>Population:</i> adults with acute traumatic brain injury and no refractory intracranial hypertension <i>Intervention:</i> neuromuscular blocking agents

	<i>Comparator:</i> no neuromuscular blocking agents <i>Primary Outcome:</i> GOS or GOS-E <i>Secondary Outcomes:</i> intracranial pressure, mortality, adverse events, hospital and ICU length of stay <i>Study design:</i> systematic review
11	<i>Population:</i> adults with acute traumatic brain injury <i>Intervention:</i> plasma transfusion <i>Comparator:</i> no plasma transfusion <i>Primary Outcome:</i> GOS or GOS-E <i>Secondary Outcomes:</i> mortality, adverse events, hospital and ICU length of stay <i>Study design:</i> systematic review
Severe traumatic brain injury	
12	<i>Population:</i> adults with acute severe traumatic brain injury <i>Intervention:</i> albumin <i>Comparator:</i> any other colloid-containing fluids (dextrans, modified gelatins, hydroxyethyl starches) or isotonic crystalloid fluids (saline 0.9% and balanced salt solutions such as compound sodium lactate, Plasma-Lyte) <i>Primary Outcome:</i> GOS or GOS-E <i>Secondary Outcomes:</i> mortality, adverse events, hospital and ICU length of stay <i>Study design:</i> systematic review
13	<i>Population:</i> adults with acute severe traumatic brain injury <i>Intervention:</i> antiseizure prophylaxis (levetiracetam or phenytoin) >1 week <i>Comparator:</i> antiseizure prophylaxis <1 week or no antiseizure prophylaxis <i>Primary Outcome:</i> late post-traumatic seizure <i>Secondary Outcomes:</i> GOS or GOS-E, mortality, adverse events, hospital and ICU length of stay <i>Study design:</i> systematic review

CCHR, Canadian Computed Tomography Head Rule; CHIP, Computed Tomography in Head Injury Patients; CNS, central nervous system; CSF, cerebrospinal fluid; CT, computed tomography; GOS, Glasgow Outcome Scale; ICU, intensive care unit; NEXUS, National Emergency X-Radiography Utilisation Study; NOC, New Orleans Criteria

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Table 2. Search strategy for hypothermia in PubMed**

Concepts	PubMed search strategy	Research
Injury	"Craniocerebral Trauma"[Majr] OR (diffus* AND axonal injur*[Title/Abstract]) OR "head trauma"[Title/Abstract] OR "head injury"[Title/Abstract] OR "head injuries"[Title/Abstract] OR "brain trauma"[Title/Abstract] OR "brain injury"[Title/Abstract] OR "brain injuries"[Title/Abstract] OR "cerebral trauma"[Title/Abstract] OR "cerebral injury"[Title/Abstract] OR "cerebral injuries"[Title/Abstract] OR "craniocerebral trauma"[Title/Abstract] OR "craniocerebral injury"[Title/Abstract] OR "craniocerebral injuries"[Title/Abstract] OR "TBI"[Title/Abstract] OR "traumatic brain injury"[Title/Abstract] OR "traumatic brain injuries"[Title/Abstract] OR "brainstem trauma"[Title/Abstract] OR "brainstem injury"[Title/Abstract] OR "brainstem injuries"[Title/Abstract] OR "Head Injuries, Closed"[MeSH:NoExp] OR "Brain Injuries"[MeSH:NoExp] OR "Craniocerebral Trauma"[MeSH:NoExp] OR "Brain Hemorrhage, Traumatic"[MeSH] OR "Diffuse Axonal Injury"[MeSH:NoExp] OR "Coma, Post-Head Injury"[MeSH:NoExp] OR "Head Injuries, Penetrating"[MeSH:NoExp] OR "Intracranial Hemorrhage, Traumatic"[MeSH] OR "Skull Fractures"[MeSH]	#1
Clinical practice	"Hypothermia"[Mesh] OR "Cryotherapy"[Mesh] OR "Body Temperature"[Mesh] OR "artificial hibernation"[Title/Abstract] OR "body cooling"[Title/Abstract] OR cold*[Title/Abstract] OR cool*[Title/Abstract] OR "cooling therapy"[Title/Abstract] OR "cooling therapies"[Title/Abstract] OR cryogen*[Title/Abstract] OR cryother*[Title/Abstract] OR cryotreat*[Title/Abstract] OR hypotherm*[Title/Abstract] OR normotherm*[Title/Abstract] OR refrigeration*[Title/Abstract] OR temperature*[Title/Abstract]	#2
Filter for systematic reviews	((((systematic review[ti] OR systematic literature review[ti] OR systematic scoping review[ti] OR systematic narrative review[ti] OR systematic qualitative review[ti] OR systematic evidence review[ti] OR systematic quantitative review[ti] OR systematic meta-review[ti] OR systematic critical review[ti] OR systematic mixed studies review[ti] OR systematic mapping review[ti] OR systematic cochrane review[ti] OR systematic search and review[ti] OR systematic integrative review[ti]) NOT comment[pt] NOT (protocol[ti] OR protocols[ti])) NOT MEDLINE [subset]) OR (Cochrane Database Syst Rev[ta] AND review[pt]) OR systematic review[pt]	#3
Total	#1 AND #2 AND #3	#4

### **Authors' contributions:**

Pier-Alexandre Tardif contributed to the elaboration of keywords, developed and tested the search strategy, drafted the manuscript and approved the final version of the manuscript.

Lynne Moore led the development of the protocol and drafted the manuscript with the first author. She acts as guarantor for the review.

François Lauzier contributed to developing keywords, validated the search strategy and the data extraction form, revised the manuscript and approved the final version.

Imen Farhat contributed to the elaboration of keywords, the search strategy and the data extraction form, critically revised and approved the final version of the manuscript.

Patrick Archambault contributed to working definitions, developed keywords, revised the manuscript and approved the final version.

François Lamontagne contributed to working definitions, developed keywords, revised the manuscript and approved the final version.

Michael Chassé validated the search strategy and the data extraction form, revised the manuscript and approved the final version.

Henry Thomas Stelfox contributed to the development of research objectives, inclusion criteria, the search strategy and the extraction form, developed keywords, revised the manuscript and approved the final version.

Belinda Gabbe elaborated inclusion and exclusion criteria and keywords, revised the manuscript and approved the final version.

Fiona Lecky elaborated inclusion and exclusion criteria and keywords, revised the manuscript and approved the final version.

John Kortbeek contributed to the development of research objectives, study definitions, inclusion criteria, and the extraction form, developed keywords, revised the manuscript and approved the final version.

Paule Lessard Bonaventure contributed to the development of research objectives and inclusion criteria, elaborated keywords, validated the data extraction form, critically revised the manuscript and approved the final version.

Catherine Truchon elaborated inclusion and exclusion criteria and keywords, contribution to the development of the conceptual framework and concept definitions, revised the manuscript and approved the final version.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Alexis F. Turgeon elaborated inclusion criteria and clinically significant outcomes, validated the search strategy, elaborated keywords, revised the manuscript and approved the final version.

**Funding statement:** This research was supported by the *Canadian Institutes of Health Research* (Foundation grant, #353374 and Embedded Clinician Researcher (PA)). Dr Moore, Lauzier, Lamontagne and Chassé are recipients of a research salary Award from the *Fonds de Recherche du Québec – Santé* (FRQS). Dr Turgeon is the Canada Research Chair in Critical Care Neurology and Trauma. The funders had no role in developing this protocol.

**Competing interests statement:** None of the authors have any conflicts of interest to declare.

**Word Count:** 1484 words.

# PRISMA-P 2015 Checklist

Section/topic	#	Checklist item	Information reported		Line number(s)
			Yes	No	
ADMINISTRATIVE INFORMATION					
Title					
Identification	1a	Identify the report as a protocol of a systematic review	X	<input type="checkbox"/>	1-2
Update	1b	If the protocol is for an update of a previous systematic review, identify as such	<input type="checkbox"/>	X	NA
Registration	2	If registered, provide the name of the registry (e.g., PROSPERO) and registration number in the Abstract	X	<input type="checkbox"/>	76-77
Authors					
Contact	3a	Provide name, institutional affiliation, and e-mail address of all protocol authors; provide physical mailing address of corresponding author	X	<input type="checkbox"/>	4-51
Contributions	3b	Describe contributions of protocol authors and identify the guarantor of the review	X	<input type="checkbox"/>	330-362
Amendments	4	If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments	<input type="checkbox"/>	X	NA
Support					
Sources	5a	Indicate sources of financial or other support for the review	X	<input type="checkbox"/>	364-370
Sponsor	5b	Provide name for the review funder and/or sponsor	X	<input type="checkbox"/>	360-363
Role of sponsor/funder	5c	Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol	X	<input type="checkbox"/>	364
INTRODUCTION					
Rationale	6	Describe the rationale for the review in the context of what is already known	X	<input type="checkbox"/>	89-118
Objectives	7	Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO)	X	<input type="checkbox"/>	117-118 150-151
METHODS					
Eligibility criteria	8	Specify the study characteristics (e.g., PICO, study design, setting, time frame) and report characteristics (e.g., years considered, language, publication status) to be used as criteria for eligibility for the review	X	<input type="checkbox"/>	129-142
Information sources	9	Describe all intended information sources (e.g., electronic databases, contact with study authors, trial registers, or other grey literature sources) with planned dates of coverage	X	<input type="checkbox"/>	148-155
Search strategy	10	Present draft of search strategy to be used for at least one electronic database, including planned	X	<input type="checkbox"/>	149-151

Section/topic	#	Checklist item	Information reported		Line number(s)
			Yes	No	
		limits, such that it could be repeated			
<b>STUDY RECORDS</b>					
Data management	11a	Describe the mechanism(s) that will be used to manage records and data throughout the review	X	<input type="checkbox"/>	157-177
Selection process	11b	State the process that will be used for selecting studies (e.g., two independent reviewers) through each phase of the review (i.e., screening, eligibility, and inclusion in meta-analysis)	X	<input type="checkbox"/>	157-165
Data collection process	11c	Describe planned method of extracting data from reports (e.g., piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators	X	<input type="checkbox"/>	167-177
Data items	12	List and define all variables for which data will be sought (e.g., PICO items, funding sources), any pre-planned data assumptions and simplifications	X	<input type="checkbox"/>	150-151 167-177
Outcomes and prioritization	13	List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale	X	<input type="checkbox"/>	150-151 167-177
Risk of bias in individual studies	14	Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis	X	<input type="checkbox"/>	179-182
<b>DATA</b>					
Synthesis	15a	Describe criteria under which study data will be quantitatively synthesized	<input type="checkbox"/>	X	NA
	15b	If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data, and methods of combining data from studies, including any planned exploration of consistency (e.g., $I^2$ , Kendall's tau)	<input type="checkbox"/>	X	NA
	15c	Describe any proposed additional analyses (e.g., sensitivity or subgroup analyses, meta-regression)	<input type="checkbox"/>	X	NA
	15d	If quantitative synthesis is not appropriate, describe the type of summary planned	X	<input type="checkbox"/>	189-193
Meta-bias(es)	16	Specify any planned assessment of meta-bias(es) (e.g., publication bias across studies, selective reporting within studies)	<input type="checkbox"/>	X	NA
Confidence in cumulative evidence	17	Describe how the strength of the body of evidence will be assessed (e.g., GRADE)	X	<input type="checkbox"/>	184-187



# BMJ Open

## Low-value clinical practices in adult traumatic brain injury: an umbrella review protocol

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-031747.R1
Article Type:	Protocol
Date Submitted by the Author:	06-Aug-2019
Complete List of Authors:	<p>Tardif, Pier-Alexandre; Population Health and Optimal Health Practices Research Unit, Trauma – Emergency – Critical Care Medicine, Centre de Recherche du CHU de Québec – Université Laval (Hôpital de l'Enfant-Jésus), Université Laval</p> <p>Moore, Lynne; Population Health and Optimal Health Practices Research Unit, Trauma – Emergency – Critical Care Medicine, Centre de Recherche du CHU de Québec – Université Laval (Hôpital de l'Enfant-Jésus), Université Laval; Department of Social and Preventative Medicine, Université Laval</p> <p>Lauzier, François; Population Health and Optimal Health Practices Research Unit, Trauma – Emergency – Critical Care Medicine, Centre de Recherche du CHU de Québec – Université Laval (Hôpital de l'Enfant-Jésus), Université Laval; Department of Social and Preventative Medicine, Université Laval</p> <p>Farhat, Imen; Population Health and Optimal Health Practices Research Unit, Trauma – Emergency – Critical Care Medicine, Centre de Recherche du CHU de Québec – Université Laval (Hôpital de l'Enfant-Jésus), Université Laval; Department of Social and Preventative Medicine, Université Laval</p> <p>Archambault, Patrick; Population Health and Optimal Health Practices Research Unit, Trauma – Emergency – Critical Care Medicine, Centre de Recherche du CHU de Québec – Université Laval (Hôpital de l'Enfant-Jésus), Université Laval; Department of Anesthesiology and Critical Care Medicine, Division of Critical Care Medicine, Université Laval</p> <p>Lamontagne, Francois; Department of Medicine, Université de Sherbrooke, 3001, 12th Avenue North</p> <p>Chassé, Michael; Department of Medicine, Université de Montréal</p> <p>Stelfox, Henry; Departments of Critical Care Medicine, Medicine and Community Health Sciences, O'Brien Institute for Public Health, University of Calgary</p> <p>Gabbe, Belinda; Monash University School of Public Health and Preventive Medicine; Farr Institute, Swansea University Medical School, Swansea University</p> <p>Lecky, Fiona; The University of Sheffield School of Health and Related Research</p> <p>Kortbeek, John; Department of Surgery, University of Calgary</p> <p>Lessard-Bonaventure, Paule; Population Health and Optimal Health Practices Research Unit, Trauma – Emergency – Critical Care Medicine, Centre de Recherche du CHU de Québec – Université Laval (Hôpital de l'Enfant-Jésus), Université Laval; Department of Surgery, Division of Neurosurgery, Université Laval</p>



	Truchon, Catherine; Institut national d'excellence en santé et en services sociaux du Québec Turgeon, Alexis; Department of Social and Preventative Medicine, Université Laval; Department of Anesthesiology and Critical Care Medicine, Division of Critical Care Medicine, Université Laval
<b>Primary Subject Heading</b>:	Epidemiology
Secondary Subject Heading:	Emergency medicine, Evidence based practice, Intensive care
Keywords:	Low-value clinical practices, traumatic brain injury, umbrella review



# LOW-VALUE CLINICAL PRACTICES IN ADULT TRAUMATIC BRAIN INJURY: AN UMBRELLA REVIEW PROTOCOL

Pier-Alexandre Tardif, MA MSc<sup>1</sup> ([pier-alexandre.tardif@crchudequebec.ulaval.ca](mailto:pier-alexandre.tardif@crchudequebec.ulaval.ca))

Lynne Moore, PhD<sup>1, 2</sup> ([lynne.moore@fmed.ulaval.ca](mailto:lynne.moore@fmed.ulaval.ca))

François Lauzier MD MSc<sup>1,3</sup> ([Francois.Lauzier@fmed.ulaval.ca](mailto:Francois.Lauzier@fmed.ulaval.ca))

Imen Farhat MSc<sup>1,2</sup> ([Imen.Farhat.1@ulaval.ca](mailto:Imen.Farhat.1@ulaval.ca))

Patrick Archambault<sup>1,3,4,5</sup> ([patrick.m.archambault@gmail.com](mailto:patrick.m.archambault@gmail.com))

François Lamontagne MD MSc<sup>6</sup> ([Francois.Lamontagne@usherbrooke.ca](mailto:Francois.Lamontagne@usherbrooke.ca))

Michael Chassé MD PhD<sup>7</sup> ([Michael.Chasse@umontreal.ca](mailto:Michael.Chasse@umontreal.ca))

Henry T Stelfox MD PhD<sup>8</sup> ([tstelfox@ucalgary.ca](mailto:tstelfox@ucalgary.ca))

Belinda Gabbe PhD<sup>9,10</sup> ([Belinda.Gabbe@monash.edu](mailto:Belinda.Gabbe@monash.edu))

Fiona Lecky MD MSc<sup>11</sup> ([f.e.lecky@sheffield.ac.uk](mailto:f.e.lecky@sheffield.ac.uk))

John Kortbeek MD<sup>12</sup> ([John.Kortbeek@albertahealthservices.ca](mailto:John.Kortbeek@albertahealthservices.ca))

Paule Lessard Bonaventure MD MSc<sup>1,13</sup> ([Paule.Lessard-Bonaventure.1@ulaval.ca](mailto:Paule.Lessard-Bonaventure.1@ulaval.ca))

Catherine Truchon PhD<sup>14</sup> ([Catherine.Truchon@inesss.qc.ca](mailto:Catherine.Truchon@inesss.qc.ca))

Alexis F Turgeon MD MSc<sup>1,2,3</sup> ([Alexis.Turgeon@fmed.ulaval.ca](mailto:Alexis.Turgeon@fmed.ulaval.ca))

on behalf of the Canadian Traumatic Brain Injury Research Consortium

<sup>1</sup>Population Health and Optimal Health Practices Research Unit, Trauma – Emergency – Critical Care Medicine, Centre de Recherche du CHU de Québec – Université Laval (Hôpital de l'Enfant-Jésus), Université Laval, Québec (QC), Canada

<sup>2</sup>Department of Social and Preventative Medicine, Université Laval, Québec (QC), Canada

<sup>3</sup>Department of Anesthesiology and Critical Care Medicine, Division of Critical Care Medicine, Université Laval, Québec City, Québec, Canada

<sup>4</sup>Centre intégré de santé et de services sociaux de Chaudière-Appalaches, Ste-Marie (QC), Canada

<sup>5</sup>Département de médecine familiale et médecine d'urgence, Université Laval, Québec (QC), Canada

<sup>6</sup>Department of Medicine, Université de Sherbrooke, 3001, 12th Avenue North, Sherbrooke, Québec, Canada

<sup>7</sup>Department of Medicine, Université de Montréal, Montréal, Québec, Canada

1  
2  
3 32 <sup>8</sup>Departments of Critical Care Medicine, Medicine and Community Health Sciences, O’Brien  
4 33 Institute for Public Health, University of Calgary, Calgary, Alberta, Canada  
5  
6 34 <sup>9</sup>School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia  
7  
8 35 <sup>10</sup>Farr Institute, Swansea University Medical School, Swansea University, Swansea, UK  
9  
10 36 <sup>11</sup>School of Health and Related Research, University of Sheffield, Sheffield, United Kingdom;  
11 Trauma Audit and Research Network, United Kingdom  
12  
13 38 <sup>12</sup>Department of Surgery, University of Calgary, Calgary, Alberta, Canada  
14  
15 39 <sup>13</sup>Department of Surgery, Division of Neurosurgery, Université Laval, Québec (QC), Canada  
16  
17 40 <sup>14</sup>Institut national d’excellence en santé et en services sociaux, Québec (QC), Canada  
18  
19 41

20 42 **Corresponding author and address for reprints:**  
21  
22 43 Pier-Alexandre Tardif  
23  
24 44 CHU de Québec-Université Laval Research Center (Enfant-Jésus Hospital)  
25  
26 45 Axe Santé des Populations et Pratiques Optimales en Santé (Population Health and Optimal Health  
27  
28 46 Practices Research Unit), Traumatologie – Urgence - Soins intensifs (Trauma – Emergency –  
29  
30 47 Critical Care Medicine)  
31  
32 48 1401, 18e rue, local H-012a, Québec (Québec), G1J 1Z4  
33  
34 49 Tel. 418-649-0252 #66605  
35  
36 50 Fax: 418-649-5733  
37  
38 51 Email: pier-alexandre.tardif@crchudequebec.ulaval.ca  
39  
40 52

41  
42 53 **Keywords:** Low-value clinical practices, traumatic brain injury, umbrella review

43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54 54 **Running head:** Umbrella review on low-value practices in acute TBI care  
55  
56  
57  
58  
59  
60

## ABSTRACT

**Introduction:** Traumatic brain injury (TBI) leads to 50,000 deaths, 85,000 disabilities and costs \$60 billion each year in the USA. Despite numerous interventions and treatment options, the outcomes of TBI have improved little over the last three decades. In a previous scoping review and expert consultation survey, we identified 15 potentially low-value clinical practices in acute TBI. The objective of this umbrella review is to synthesise the evidence on potentially low-value clinical practices in the care of acute TBI.

**Methods and analysis:** Using umbrella review methodology, we will search Cochrane CENTRAL, EMBASE, Epistemonikos, PROSPERO and PubMed to identify systematic reviews evaluating the effect of potential intra-hospital low-value practices using tailored PICOS questions based on the results of a previous scoping review. We will present data on the methodological quality of these reviews (AMSTAR-2), reported effect sizes and the strength of evidence (GRADE).

**Ethics and dissemination:** Ethics approval is not required as original data will not be collected. Knowledge users from five healthcare quality organisations and clinical associations are involved in the design and conduct of the study. Results will be disseminated in a peer-reviewed journal, at international scientific meetings and to clinical, healthcare quality and patient-partner associations. This work will support the development of metrics to measure the use of low-value practices, inform policy makers on potential targets for de-implementation, and in the long term reduce the use of low-value clinical practices in acute TBI care.

**Registration details:** The protocol has been registered with the International Prospective Register of Systematic Reviews (PROSPERO, CRD42019132428).

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

STRENGTHS AND LIMITATIONS OF THIS STUDY

- State-of-the-art synthesis of evidence on low-value clinical practices in the care of acute TBI
- Represents a crucial step towards the de-implementation of low-value practices in acute TBI care
- Adopts an integrated knowledge translation model to ensure the results are relevant to decision makers
- For feasibility reasons, our synthesis is restricted to systematic reviews published in English since 1990
- The scope of review and the inclusion of systematic reviews precludes meta-analysis

## INTRODUCTION

Traumatic brain injury (TBI) is the main cause of mortality from injury in people under 45 years of age[1] and it leads to approximately US\$60 and €33 billion in total medical costs in the USA[2] and Europe[3] each year, respectively. Moreover, outcomes following TBI have not improved significantly in the last four decades.[4, 5] Intervention and treatment options for TBI are multiple, but many lack robust evidence of their effectiveness.[6, 7]

Low-value clinical practices, defined as a test or procedure that is not supported by evidence and/or could expose patients to unnecessary harm [8-15] consume up to 30% of healthcare budgets.[9, 16] In the past decade, the medical community has turned towards the de-implementation of low-value practices as a promising means to reduce the strain on healthcare budgets, free-up resources and reduce harm to patients.[17] Physicians report using low-value practices because of a lack of alternative treatment options, fear of legal consequences but also because of lack of guidelines on low-value care.[15, 18] The *Brain Trauma Foundation*, among others, publish guidelines on TBI care.[19] However, emphasis is on practices that should be adhered to rather than practices that should be avoided. *Choosing Wisely* publish recommendations specifically targeting low-value practices but few pertain to TBI care and many are based uniquely on expert consensus.[11] A previous scoping review and expert consultation survey identified 13 potentially low-value clinical practices in acute TBI care.[20] These practices represent potential targets for guidelines, overuse metrics and de-implementation interventions. However, before recommendations can be made, we need to synthesise the evidence base for these practices.

Interventions and treatment options for acute TBI have been the subject of multiple systematic reviews.[21, 22] Given this large body of available evidence, evidence maps have previously been used to summarize evidence from systematic reviews on acute TBI interventions.[7, 23] However, these evidence maps were not designed to target low-value practices and focused on moderate to severe TBI when the mild TBI population represent great potential for reducing low-value care. In addition, previous reviews have not provided a synthesis of effect sizes or strength of evidence. The objective of the present study is to synthesise the evidence on potentially low-value intra-hospital clinical practices in acute adult TBI.

METHODS AND ANALYSIS

Given the multitude of systematic reviews available for the clinical practices identified as potentially low-value (over 60 were identified in our scoping review), we opted to conduct an umbrella review (a systematic review of systematic reviews).[20] While the former aimed to fill a knowledge gap on medical overuse for acute injury care by identifying all potential low-value clinical practices, the latter will synthesise the evidence on the low-value practices pertaining to TBI. The review will be conducted according to published guidelines.[24-26] In the absence of reporting guidelines for umbrella reviews, we will use the applicable Preferred Reporting Items for Systematic Reviews and Meta-Analysis Protocols (PRISMA-P).[27] The protocol has been registered with the International Prospective Register of Systematic Reviews (PROSPERO, CRD42019132428).

Eligibility criteria

The project steering committee comprising clinicians (2 emergency physicians, 7 critical care physicians, 1 neurosurgeon), methodologists (4), and health system managers (3) used the population, intervention, comparator, outcome and study design (PICOS) framework to develop specific research questions for each potentially low-value clinical practice (Table 1).[20, 28] We will consider systematic reviews of original studies evaluating the effectiveness of pre-determined clinical practices in acute TBI in adults (≥ 16 years old), without restriction on location of publication but limited to studies published in English since 1990.[25, 26]

We will use the Cochrane definition to identify systematic reviews. We will consider a review to be systematic if it clearly stated a set of objectives and reported explicit eligibility criteria, an extensive search strategy (a refined search strategy ran on MEDLINE or Cochrane Library and at least one other database)[29, 30] and reproducible methods to identify, select, and critically appraise the findings of the included studies.[24]

Outcomes

Primary and secondary outcomes were identified for each of the evaluated clinical practices by the project steering committee and are described in a PICO format in Table 1.

## 149 Search strategy

150 In consultation with an information specialist, we will develop comprehensive literature search  
151 strategies separately for each clinical practice to be studied (see Table 2 for a preliminary search  
152 strategy in PubMed). We will search systematic reviews using the Cochrane Library, Excerpta  
153 Medica Database (EMBASE), Epistemonikos,[31] PubMed and the International Prospective  
154 Register of Systematic Reviews (PROSPERO)[32] from 1990 to up to six months prior to  
155 submission for publication. Using a snowball approach, we will screen the references of included  
156 studies in addition to previous reviews on this subject.[7, 21-23, 33]

## 158 Selection process

159 We will manage all citations with EndNote software (version X8.2, Clarivate Analytics, 2014). We  
160 will identify and remove duplicates using electronic and manual screening.[34] To ensure  
161 reliability when selecting studies for a given practice, two sets of 100 citations will independently  
162 be evaluated and then discussed by the reviewers. Pairs of reviewers (PAT, LM, IF, KMB) will  
163 then independently screen all identified records using titles, abstracts and full texts, consecutively.  
164 Any disagreement will be resolved through discussion between reviewers and, if necessary,  
165 consultation with a senior author (AFT). Potentially eligible studies excluded using full texts will  
166 be described in a PRISMA flow chart.

## 168 Data items and abstraction process

169 Using a standardized data abstraction form piloted on a representative sample of 5 studies, pairs of  
170 experienced reviewers (PAT, LM, IF, KMB) will independently extract the following data: first  
171 author, title, year of publication, databases used and date of the last search; population(s),  
172 intervention(s), comparator(s), outcome(s) and study designs included; measures of association and  
173 their respective measure of heterogeneity; tools used to assess the quality (risk of bias) of original  
174 studies and overall rating from the authors. Any disagreement will be resolved through discussion  
175 between reviewers and, if necessary, consultation with a senior author (AFT). When information  
176 is available in figures only, we will abstract graphical data using computer-assisted software.[35,  
177 36] Furthermore, we will contact study authors (up to three email attempts) when information is  
178 unclear or unavailable.



**Methodological quality assessment**

Two reviewers (PAT, LM) will independently critically appraise the quality of systematic reviews using the Assessing the Methodological Quality of Systematic Reviews (AMSTAR-2) tool.[37] Methodological quality will be categorised as low (0-3), medium (4-7) and high (8-11).

**Synthesis**

Results will be presented according to current recommendations for umbrella reviews.[38] For each low-value practice, we will present the number of studies, study designs, and patients included, the quality of the reviews (AMSTAR-2), effect sizes for primary and secondary outcomes (forest plots) and strength of recommendations (GRADE).

**Potential limitations**

To ensure the feasibility of the review, we will restrict our search to low-value practices identified in the scoping review and expert consultation study, which may lead us to miss some low-value practices. However, given the robust search strategy used in our scoping review and the fact that experts were asked to add any other practices they considered low-value, it is unlikely that important low-value practices have been missed. By targeting systematic reviews rather than original studies, we may miss some evidence. However, given the availability of high-quality, up-to-date reviews in TBI care suggested by our scoping review, we think it unlikely that we will miss a large body of evidence. For certain clinical practices, we may not identify any high-quality, up-to-date reviews. These practices will be the subject of systematic reviews in subsequent phases of the research program. Finally, for feasibility reasons, we limited this umbrella review to reviews published in English since 1990 as per recommendations for umbrella reviews.[25, 26] These limitations should have negligible impact on results since few systematic reviews were published prior to 1990 and most published reviews are likely to be written in English.[25, 26]

**Potential impact**

This review is part of the *Canadian Program on Monitoring Low-Value Clinical Practices in Injury Care* (Canadian Institutes of Health Research #113664), aiming to evaluate the effectiveness of an audit-feedback module targeting low-value clinical practices in acute injury care. The results of

1  
2  
3 210 this review will be used to inform the development of quality indicators to be integrated in the  
4  
5 211 audit-feedback module.

6 212  
7  
8 213 We will use state-of-the-art methods to optimize the sensitivity of our search strategy and the  
9  
10 214 robustness of results. Results will be synthesised graphically. Ultimately, this research will inform  
11  
12 215 the development of metrics, guidelines and de-implementation interventions, all targeting low-  
13  
14 216 value injury care. The reduction of low-value clinical practices in acute TBI care has the potential  
15  
16 217 to reduce pressure on strained healthcare budgets, free up resources, reduce adverse events and  
17  
18 218 improve patient outcomes.

19 219  
20 220 **ETHICS AND DISSEMINATION**

21  
22 221 Ethics approval is not required as original data will not be collected. This study will be  
23  
24 222 disseminated in a peer-reviewed journal, international scientific meetings, to knowledge users  
25  
26 223 through clinical and healthcare quality associations (Choosing Wisely Canada, Trauma Association  
27  
28 224 of Canada, American College of Surgeons – Committee on Trauma, International Federation of  
29  
30 225 Emergency Medicine, Institut national d'excellence en santé et en services sociaux, Brain Trauma  
31  
32 226 Foundation) and to patient partners associations (Brain Injury Canada).

33 227  
34 228 **Patient and Public Involvement**

35  
36 229 No patient or public representatives will be involved in this study.  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

REFERENCES

1. The American Association for the Surgery of Trauma (AAST). Traumatic Brain Injury in the United States: A Report to Congress, CDC, December 1999 [cited 2018 November 19]. Available from: <http://www.aast.org/trauma-facts>.

2. Coronado VG, Haileyesus T, Cheng TA, et al. Trends in Sports- and Recreation-Related Traumatic Brain Injuries Treated in US Emergency Departments: The National Electronic Injury Surveillance System-All Injury Program (NEISS-AIP) 2001-2012. *J Head Trauma Rehabil* 2015;30(3):185-97.

3. Olesen J, Gustavsson A, Svensson M, et al. The economic cost of brain disorders in Europe. *Eur J Neurol* 2012;19(1):155-62.

4. Rosenfeld JV, Maas AI, Bragge P, et al. Early management of severe traumatic brain injury. *Lancet* 2012;380(9847):1088-98.

5. Maas AIR, Menon DK, Adelson PD, et al. Traumatic brain injury: integrated approaches to improve prevention, clinical care, and research. *Lancet Neurol* 2017;16(12):987-1048.

6. Maas AI, Roozenbeek B, Manley GT. Clinical trials in traumatic brain injury: past experience and current developments. *Neurotherapeutics* 2010;7(1):115-26.

7. Bragge P, Synnot A, Maas AI, et al. A State-of-the-Science Overview of Randomized Controlled Trials Evaluating Acute Management of Moderate-to-Severe Traumatic Brain Injury. *J Neurotrauma* 2016;33(16):1461-78.

8. Boat TF, Chao SM, O'Neill PH. From waste to value in health care. *JAMA* 2008;299(5):568-71.

9. Reilly BM, Evans AT. Much ado about (doing) nothing. *Annals of internal medicine* 2009;150(4):270-1.

10. Berwick DM, Hackbarth AD. Eliminating waste in US health care. *JAMA* 2012;307(14):1513-6.

11. Choosing Wisely Canada. 2015 [cited 2018 November 19]. Available from: <https://choosingwiselycanada.org/>.

12. Morgan DJ, Dhruva SS, Wright SM, et al. 2016 Update on Medical Overuse: A Systematic Review. *JAMA Intern Med* 2016;176(11):1687-92.

13. Berwick DM. Avoiding overuse-the next quality frontier. *Lancet* 2017;390(10090):102-4.

14. Brownlee S, Chalkidou K, Doust J, et al. Evidence for overuse of medical services around the world. *Lancet* 2017;390(10090):156-68.

15. Saini V, Brownlee S, Elshaug AG, et al. Addressing overuse and underuse around the world. *Lancet* 2017;390(10090):105-7.

16. Fisher ES, Wennberg DE, Stukel TA, et al. The implications of regional variations in Medicare spending. Part 2: health outcomes and satisfaction with care. *Annals of internal medicine* 2003;138(4):288-98.

17. Niven DJ, Mrklas KJ, Holodinsky JK, et al. Towards understanding the de-adoption of low-value clinical practices: a scoping review. *BMC Med* 2015;13:255.

18. Emanuel EJ, Fuchs VR. The perfect storm of overutilization. *JAMA* 2008;299(23):2789-91.

19. Carney N, Totten AM, O'Reilly C, et al. Guidelines for the Management of Severe Traumatic Brain Injury, Fourth Edition. *Neurosurgery* 2017;80(1):6-15.

20. Moore L, Lauzier F, Tardif PA, et al. Low-Value Clinical Practices in Injury Care: A Scoping Review and Expert Consultation Survey. *J Trauma Acute Care Surg* 2019.

21. Lei J, Gao GY, Jiang JY. Is management of acute traumatic brain injury effective? A literature review of published Cochrane Systematic Reviews. *Chin J Traumatol* 2012;15(1):17-22.
22. Lu J, Gary KW, Copolillo A, et al. Randomized controlled trials in adult traumatic brain injury: a review of compliance to CONSORT statement. *Arch Phys Med Rehabil* 2015;96(4):702-14.
23. Synnot A, Bragge P, Lunney C, et al. The currency, completeness and quality of systematic reviews of acute management of moderate to severe traumatic brain injury: A comprehensive evidence map. *PLoS One* 2018;13(6):e0198676.
24. Higgins J, Green S, (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. Higgins J, Green S, editors: The Cochrane Collaboration; 2011.
25. Smith V, Devane D, Begley CM, et al. Methodology in conducting a systematic review of systematic reviews of healthcare interventions. *BMC Med Res Methodol* 2011;11(1):15.
26. The Joanna Briggs Institute. Joanna Briggs Institute Reviewers' Manual: 2014 edition / Supplement. *The Joanna Briggs Institute* 2014.
27. Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. *Syst Rev* 2015;4:1.
28. Stone PW. Popping the (PICO) question in research and evidence-based practice. *Appl Nurs Res* 2002;15(3):197-8.
29. Marshall I, Marshall R, Wallace B, et al. Rapid reviews may produce different results to systematic reviews: a meta-epidemiological study. *J Clin Epidemiol* 2018.
30. Bramer WM, Rethlefsen ML, Kleijnen J, et al. Optimal database combinations for literature searches in systematic reviews: a prospective exploratory study. *Systematic reviews* 2017;6(1):245-.
31. Epistemonikos. Epistemonikos n.d. [cited 2018 November 19]. Available from: <http://www.epistemonikos.org/en/>.
32. Centre for Reviews and Dissemination. PROSPERO [cited 2018 November 19]. Available from: <https://www.crd.york.ac.uk/PROSPERO/>.
33. Horton L, Rhodes J, Wilson L. Randomized Controlled Trials in Adult Traumatic Brain Injury: A Systematic Review on the Use and Reporting of Clinical Outcome Assessments. *J Neurotrauma* 2018;35(17):2005-14.
34. Bramer WM, Giustini D, de Jonge GB, et al. De-duplication of database search results for systematic reviews in EndNote. *J Med Libr Assoc* 2016;104(3):240-3.
35. de Oliveira IR, Santos-Jesus R, Po AL, et al. Extracting numerical data from published reports of pharmacokinetics investigations: method description and validation. *Fundam Clin Pharmacol* 2003;17(4):471-2.
36. Robson RC, Pham B, Hwee J, et al. Few studies exist examining methods for selecting studies, abstracting data, and appraising quality in a systematic review. *J Clin Epidemiol* 2018.
37. Shea BJ, Reeves BC, Wells G, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. *BMJ* 2017;358:j4008.
38. Lunney C, Brennan SE, McDonald S, et al. Toward a comprehensive evidence map of overview of systematic review methods: paper 2-risk of bias assessment; synthesis, presentation and summary of the findings; and assessment of the certainty of the evidence. *Syst Rev* 2018;7(1):159.

321 **Tables**

322 **Table 1. PICOS for each clinical practice**

323

#	Clinical practice
Mild traumatic brain injury	
1	<i>Population:</i> adults with acute mild traumatic brain injury <i>Intervention:</i> validated clinical decision rule (e.g. CCHR, CHIP, NEXUS II, NOC) <i>Comparator:</i> none <i>Primary Outcome:</i> false negative rate (intracranial injury, neurosurgical intervention) <i>Secondary Outcomes:</i> sensitivity, specificity <i>Study design:</i> systematic review
2	<i>Population:</i> adults with acute mild complicated traumatic brain injury <i>Intervention:</i> routine repeat head CT in absence of neurological deterioration <i>Comparator:</i> none or no repeat head CT in absence of neurological deterioration <i>Primary Outcome:</i> progression of intracranial injury <i>Secondary Outcomes:</i> neurosurgical intervention, mortality, change in management, hospital length of stay <i>Study design:</i> systematic review
3	<i>Population:</i> adults with acute mild traumatic brain injury and on anticoagulant and/or antiplatelet therapy <i>Intervention:</i> : routine repeat head CT in absence of neurological deterioration <i>Comparator:</i> none or no repeat head CT in absence of neurological deterioration <i>Primary Outcome:</i> progression of intracranial injury <i>Secondary Outcomes:</i> neurosurgical intervention, mortality, change in management, hospital length of stay <i>Study design:</i> systematic review
4	<i>Population:</i> adults with acute mild traumatic brain injury who are negative on head CT <i>Intervention:</i> neurosurgical consultation <i>Comparator:</i> none or no neurosurgical consultation <i>Primary Outcome:</i> hospital admission <i>Secondary Outcomes:</i> neurosurgical intervention, mortality, ICU admission, repeat head CT, hospital length of stay <i>Study design:</i> systematic review
5	<i>Population:</i> adults with acute mild complicated traumatic brain injury who are not on irreversible anticoagulation <i>Intervention:</i> intensive care unit admission

	<p><i>Comparator:</i> admission to regular ward or step-down unit</p> <p><i>Primary Outcome:</i> neurological/medical decline, neurosurgical intervention</p> <p><i>Secondary Outcomes:</i> medical interventions, mortality, adverse events, hospital length of stay, discharge destination</p> <p><i>Study design:</i> systematic review</p>
	Moderate and severe traumatic brain injury
6	<p><i>Population:</i> adults with acute traumatic brain injury on antiplatelet therapy</p> <p><i>Intervention:</i> platelet transfusion</p> <p><i>Comparator:</i> no platelet transfusion</p> <p><i>Primary Outcome:</i> GOS or GOS-E</p> <p><i>Secondary Outcomes:</i> mortality, adverse events, hospital and ICU length of stay</p> <p><i>Study design:</i> systematic review</p>
7	<p><i>Population:</i> adults with basal skull fractures without evidence of cerebrospinal fluid leakage</p> <p><i>Intervention:</i> antibiotic prophylaxis</p> <p><i>Comparator:</i> no antibiotic prophylaxis</p> <p><i>Primary Outcome:</i> meningitis (confirmed by lumbar puncture)</p> <p><i>Secondary Outcomes:</i> GOS or GOS-E, mortality, surgical correction in patients with CSF leakage, non-CNS infection, hospital and ICU length of stay</p> <p><i>Study design:</i> systematic review</p>
8	<p><i>Population:</i> adults with acute traumatic brain injury and no refractory intracranial hypertension</p> <p><i>Intervention:</i> therapeutic hypothermia</p> <p><i>Comparator:</i> no therapeutic hypothermia</p> <p><i>Primary Outcome:</i> GOS or GOS-E</p> <p><i>Secondary Outcomes:</i> intracranial pressure, mortality, adverse events, hospital and ICU length of stay</p> <p><i>Study design:</i> systematic review</p>
9	<p><i>Population:</i> adults with acute traumatic brain injury</p> <p><i>Intervention:</i> antibiotic prophylaxis for external ventricular drain placement</p> <p><i>Comparator:</i> no antibiotic prophylaxis</p> <p><i>Primary Outcome:</i> ventriculostomy-related infection</p> <p><i>Secondary Outcomes:</i> GOS, mortality, hospital and ICU length of stay</p> <p><i>Study design:</i> systematic review</p>
10	<p><i>Population:</i> adults with acute traumatic brain injury and no refractory intracranial hypertension</p> <p><i>Intervention:</i> neuromuscular blocking agents</p>



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

	<i>Comparator:</i> no neuromuscular blocking agents <i>Primary Outcome:</i> GOS or GOS-E <i>Secondary Outcomes:</i> intracranial pressure, mortality, adverse events, hospital and ICU length of stay <i>Study design:</i> systematic review
11	<i>Population:</i> adults with acute traumatic brain injury <i>Intervention:</i> plasma transfusion <i>Comparator:</i> no plasma transfusion <i>Primary Outcome:</i> GOS or GOS-E <i>Secondary Outcomes:</i> mortality, adverse events, hospital and ICU length of stay <i>Study design:</i> systematic review
Severe traumatic brain injury	
12	<i>Population:</i> adults with acute severe traumatic brain injury <i>Intervention:</i> albumin <i>Comparator:</i> any other colloid-containing fluids (dextrans, modified gelatins, hydroxyethyl starches) or isotonic crystalloid fluids (saline 0.9% and balanced salt solutions such as compound sodium lactate, Plasma-Lyte) <i>Primary Outcome:</i> GOS or GOS-E <i>Secondary Outcomes:</i> mortality, adverse events, hospital and ICU length of stay <i>Study design:</i> systematic review
13	<i>Population:</i> adults with acute severe traumatic brain injury <i>Intervention:</i> antiseizure prophylaxis (levetiracetam or phenytoin) >1 week <i>Comparator:</i> antiseizure prophylaxis <1 week or no antiseizure prophylaxis <i>Primary Outcome:</i> late post-traumatic seizure <i>Secondary Outcomes:</i> GOS or GOS-E, mortality, adverse events, hospital and ICU length of stay <i>Study design:</i> systematic review

CCHR, Canadian Computed Tomography Head Rule; CHIP, Computed Tomography in Head Injury Patients; CNS, central nervous system; CSF, cerebrospinal fluid; CT, computed tomography; GOS, Glasgow Outcome Scale; ICU, intensive care unit; NEXUS, National Emergency X-Radiography Utilisation Study; NOC, New Orleans Criteria

Table 2. Search strategy for hypothermia in PubMed

Concepts	PubMed search strategy	Research
Injury	"Craniocerebral Trauma"[Majr] OR (diffus* AND axonal injur*[Title/Abstract]) OR "head trauma"[Title/Abstract] OR "head injury"[Title/Abstract] OR "head injuries"[Title/Abstract] OR "brain trauma"[Title/Abstract] OR "brain injury"[Title/Abstract] OR "brain injuries"[Title/Abstract] OR "cerebral trauma"[Title/Abstract] OR "cerebral injury"[Title/Abstract] OR "cerebral injuries"[Title/Abstract] OR "craniocerebral trauma"[Title/Abstract] OR "craniocerebral injury"[Title/Abstract] OR "craniocerebral injuries"[Title/Abstract] OR "TBI"[Title/Abstract] OR "traumatic brain injury"[Title/Abstract] OR "traumatic brain injuries"[Title/Abstract] OR "brainstem trauma"[Title/Abstract] OR "brainstem injury"[Title/Abstract] OR "brainstem injuries"[Title/Abstract] OR "Head Injuries, Closed"[MeSH:NoExp] OR "Brain Injuries"[MeSH:NoExp] OR "Craniocerebral Trauma"[MeSH:NoExp] OR "Brain Hemorrhage, Traumatic"[MeSH] OR "Diffuse Axonal Injury"[MeSH:NoExp] OR "Coma, Post-Head Injury"[MeSH:NoExp] OR "Head Injuries, Penetrating"[MeSH:NoExp] OR "Intracranial Hemorrhage, Traumatic"[MeSH] OR "Skull Fractures"[MeSH]	#1
Clinical practice	"Hypothermia"[Mesh] OR "Cryotherapy"[Mesh] OR "Body Temperature"[Mesh] OR "artificial hibernation"[Title/Abstract] OR "body cooling"[Title/Abstract] OR cold*[Title/Abstract] OR cool*[Title/Abstract] OR "cooling therapy"[Title/Abstract] OR "cooling therapies"[Title/Abstract] OR cryogen*[Title/Abstract] OR cryother*[Title/Abstract] OR cryotreat*[Title/Abstract] OR hypotherm*[Title/Abstract] OR normotherm*[Title/Abstract] OR refrigeration*[Title/Abstract] OR temperature*[Title/Abstract]	#2
Filter for systematic reviews	((systematic review[ti] OR systematic literature review[ti] OR systematic scoping review[ti] OR systematic narrative review[ti] OR systematic qualitative review[ti] OR systematic evidence review[ti] OR systematic quantitative review[ti] OR systematic meta-review[ti] OR systematic critical review[ti] OR systematic mixed studies review[ti] OR systematic mapping review[ti] OR systematic cochrane review[ti] OR systematic search and review[ti] OR systematic integrative review[ti]) NOT comment[pt] NOT (protocol[ti] OR protocols[ti])) NOT MEDLINE [subset] OR (Cochrane Database Syst Rev[ta] AND review[pt]) OR systematic review[pt]	#3
Total	#1 AND #2 AND #3	#4



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Authors' contributions:**

Pier-Alexandre Tardif contributed to the elaboration of keywords, developed and tested the search strategy, drafted the manuscript and approved the final version of the manuscript.

Lynne Moore led the development of the protocol and drafted the manuscript with the first author. She acts as guarantor for the review.

François Lauzier contributed to developing keywords, validated the search strategy and the data extraction form, revised the manuscript and approved the final version.

Imen Farhat contributed to the elaboration of keywords, the search strategy and the data extraction form, critically revised and approved the final version of the manuscript.

Patrick Archambault contributed to working definitions, developed keywords, revised the manuscript and approved the final version.

François Lamontagne contributed to working definitions, developed keywords, revised the manuscript and approved the final version.

Michael Chassé validated the search strategy and the data extraction form, revised the manuscript and approved the final version.

Henry Thomas Stelfox contributed to the development of research objectives, inclusion criteria, the search strategy and the extraction form, developed keywords, revised the manuscript and approved the final version.

Belinda Gabbe elaborated inclusion and exclusion criteria and keywords, revised the manuscript and approved the final version.

Fiona Lecky elaborated inclusion and exclusion criteria and keywords, revised the manuscript and approved the final version.

John Kortbeek contributed to the development of research objectives, study definitions, inclusion criteria, and the extraction form, developed keywords, revised the manuscript and approved the final version.

Paule Lessard Bonaventure contributed to the development of research objectives and inclusion criteria, elaborated keywords, validated the data extraction form, critically revised the manuscript and approved the final version.

Catherine Truchon elaborated inclusion and exclusion criteria and keywords, contribution to the development of the conceptual framework and concept definitions, revised the manuscript and approved the final version.

Alexis F. Turgeon elaborated inclusion criteria and clinically significant outcomes, validated the search strategy, elaborated keywords, revised the manuscript and approved the final version.

**Funding statement:** This research was supported by the *Canadian Institutes of Health Research* (Foundation grant, #353374 and Embedded Clinician Researcher (PA)). Dr Moore, Lauzier, Lamontagne and Chassé are recipients of a research salary Award from the *Fonds de Recherche du Québec – Santé* (FRQS). Dr Turgeon is the Canada Research Chair in Critical Care Neurology and Trauma. The funders had no role in developing this protocol.

**Competing interests statement:** None of the authors have any conflicts of interest to declare.

**Word Count:** 1494 words.

PRISMA-P 2015 Checklist

Section/topic	#	Checklist item	Information reported		Line number(s)
			Yes	No	
ADMINISTRATIVE INFORMATION					
Title					
Identification	1a	Identify the report as a protocol of a systematic review	X	<input type="checkbox"/>	1-2
Update	1b	If the protocol is for an update of a previous systematic review, identify as such	<input type="checkbox"/>	X	NA
Registration	2	If registered, provide the name of the registry (e.g., PROSPERO) and registration number in the Abstract	X	<input type="checkbox"/>	76-77
Authors					
Contact	3a	Provide name, institutional affiliation, and e-mail address of all protocol authors; provide physical mailing address of corresponding author	X	<input type="checkbox"/>	4-51
Contributions	3b	Describe contributions of protocol authors and identify the guarantor of the review	X	<input type="checkbox"/>	339-371
Amendments	4	If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments	<input type="checkbox"/>	X	NA
Support					
Sources	5a	Indicate sources of financial or other support for the review	X	<input type="checkbox"/>	373-377
Sponsor	5b	Provide name for the review funder and/or sponsor	X	<input type="checkbox"/>	373-377
Role of sponsor/funder	5c	Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol	X	<input type="checkbox"/>	377
INTRODUCTION					
Rationale	6	Describe the rationale for the review in the context of what is already known	X	<input type="checkbox"/>	87-116
Objectives	7	Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO)	X	<input type="checkbox"/>	115-116 146-147
METHODS					
Eligibility criteria	8	Specify the study characteristics (e.g., PICO, study design, setting, time frame) and report characteristics (e.g., years considered, language, publication status) to be used as criteria for eligibility for the review	X	<input type="checkbox"/>	130-137
Information sources	9	Describe all intended information sources (e.g., electronic databases, contact with study authors, trial registers, or other grey literature sources) with planned dates of coverage	X	<input type="checkbox"/>	148-155
Search strategy	10	Present draft of search strategy to be used for at least one electronic database, including planned	X	<input type="checkbox"/>	149-156

Section/topic	#	Checklist item	Information reported		Line number(s)
			Yes	No	
		limits, such that it could be repeated			
<b>STUDY RECORDS</b>					
Data management	11a	Describe the mechanism(s) that will be used to manage records and data throughout the review	X	<input type="checkbox"/>	158-177
Selection process	11b	State the process that will be used for selecting studies (e.g., two independent reviewers) through each phase of the review (i.e., screening, eligibility, and inclusion in meta-analysis)	X	<input type="checkbox"/>	158-166
Data collection process	11c	Describe planned method of extracting data from reports (e.g., piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators	X	<input type="checkbox"/>	168-178
Data items	12	List and define all variables for which data will be sought (e.g., PICO items, funding sources), any pre-planned data assumptions and simplifications	X	<input type="checkbox"/>	145-147 168-178
Outcomes and prioritization	13	List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale	X	<input type="checkbox"/>	145-147 168-178
Risk of bias in individual studies	14	Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis	X	<input type="checkbox"/>	180-183
<b>DATA</b>					
Synthesis	15a	Describe criteria under which study data will be quantitatively synthesized	<input type="checkbox"/>	X	NA
	15b	If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data, and methods of combining data from studies, including any planned exploration of consistency (e.g., $I^2$ , Kendall's tau)	<input type="checkbox"/>	X	NA
	15c	Describe any proposed additional analyses (e.g., sensitivity or subgroup analyses, meta-regression)	<input type="checkbox"/>	X	NA
	15d	If quantitative synthesis is not appropriate, describe the type of summary planned	X	<input type="checkbox"/>	185-189
Meta-bias(es)	16	Specify any planned assessment of meta-bias(es) (e.g., publication bias across studies, selective reporting within studies)	<input type="checkbox"/>	X	NA
Confidence in cumulative evidence	17	Describe how the strength of the body of evidence will be assessed (e.g., GRADE)	X	<input type="checkbox"/>	185-189